Early results presented from the RESET-SSc trial showed that two people with systemic sclerosis (scleroderma) experienced reduced skin thickening after receiving rese-cel, an investigational CAR T-cell therapy. Both were also able to stop using immunosuppressive medications and steroids.
“I am optimistic that CAR T and other cellular therapies can lead to drug free remission and potential cure in people with progressive and severe systemic sclerosis,” says Dinesh Khanna, MD, Director of the University of Michigan Scleroderma Program and SRF-funded investigator, who presented the data at EULAR 2025 in Barcelona. “Large, well-designed trials are needed to fully assess risks and benefits of cellular therapies in autoimmune diseases.”
Read the full article to learn more about this promising research: https://sclerodermanews.com/news/car-t-cell-therapy-rese-cel-shows-efficacy-systemic-sclerosis/
